Iloperidone 133454-47-4

簡要描述：Iloperidone 133454-47-4
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms.

產(chǎn)品型號：abs47027746
廠商性質(zhì)：生產(chǎn)廠家
更新時間：2025-12-29
訪問量：601

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

生化試劑

其它生化試劑植物提取物碳水化合物生物緩沖劑熒光探針與染料表面活性劑酶&輔酶&酶底物蛋白質(zhì)組學動植物激素小分子化合物生化檢測試劑盒逆行示蹤劑抗生素核苷&核苷酸多肽

查看全部

相關(guān)文章

詳細介紹

品牌	absin	CAS	133454-47-4
分子式	C24H27FN2O4	純度	＞98%
分子量	426.48	貨號	abs47027746
規(guī)格	5mg	供貨周期	現(xiàn)貨
主要用途	is an atypical antipsychotic	應用領(lǐng)域	化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合

Iloperidone 133454-47-4

產(chǎn)品描述
描述	Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. made initial inquiries into the drug; however, in May 1996, they discontinued research, and in June 1997 gave research rights to Titan Pharmaceuticals. Titan then handed over worldwide development, manufacturing and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals announced that the Phase III development rights have been acquired by Vanda Pharmaceuticals. FDA approved on May 9, 2009.
純度	＞98%
儲存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
別名	伊潘立酮；HP 873
外觀	白色至灰白色結(jié)晶粉末
可溶性/溶解性	DMSO : 26 mg/mL (61 mM) Ethanol : 4 mg/mL (9.37 mM)
生物活性
靶點	5-HT
In vitro(體外研究)	Iloperidone displays high affinity (Ki Iloperidone displays higher affinity for the dopamine D3 receptor (Ki = 7.1 nM) than for the dopamine D4 receptor (Ki = 25 nM). Iloperidone displays high affinity for the 5-HT6 and 5-HT7 receptors (Ki = 42.7 nM and 21.6 nM, respectively), and is found to have higher affinity for the 5-HT2A (Ki = 5.6 nM) than for the 5-HT2C receptor (Ki = 42.8 nM). Iloperidone significantly increases dopa accumulation, an index of dopamine turnover in response to D2 receptor blockade, at doses from 0.3 mg/kg to 10 mg/kg i.p. in the striatum and from 1 mg/kg to 10 mg/kg in the nucleus accumbens.
In vivo(體內(nèi)研究)	Iloperidone exerts behavioral effects in pharmacological rats models of disrupted sensorimotor gating consistent with "atypical" antipsychotics, mediated by antagonism of dopaminergic and noradrenergic receptors. Iloperidone (1 and 3 mg/kg) prevents the PPI-disruptive effects of treatment with 1 mg/kg PCP. Iloperidone (0.3 mg/kg) prevents cirazoline-induced PPI deficits, independent of its effects on startle magnitude. Iloperidone (10 mg/kg) and Melperone (10 mg/kg) produce an equivalent or a smaller increase in DA release in the nucleus accumbens (NAC) of rats, respectively, compared to the mPFC, whereas none of them increase acetylcholine (ACh) release in the NAC.
參考文獻
參考文獻	1. George M, et al. Eur J Clin Pharmacol. 2013 Apr 2. 2. Kongsamut S, et al. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. 3. Bobo WV. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91.

研究領(lǐng)域
研究領(lǐng)域	MetabolismTypes of diseaseObesity NeuroscienceProcesses NeuroscienceNeurology processMetabolism NeuroscienceNeurotransmissionReceptors / ChannelsGPCRSerotonin Receptors Signal TransductionSignaling PathwayG Protein SignalingGPCR Drug DiscoverySmall Molecule DrugLead Compound Discovery

Iloperidone 133454-47-4溫馨提示：本產(chǎn)品僅作科研實驗使用，不支持臨床等研究

產(chǎn)品咨詢

留言框

產(chǎn)品：
您的單位：
您的姓名：
聯(lián)系電話：
常用郵箱：
省份：
詳細地址：
補充說明：
驗證碼：

請輸入計算結(jié)果（填寫阿拉伯數(shù)字），如：三加四=7

上一篇：abs47027744Promestriene 39219-28-8
下一篇：abs47027747Doxepin Hydrochloride 1229-29-4

Iloperidone 133454-47-4

留言框

產(chǎn)品：

您的單位：

您的姓名：

聯(lián)系電話：

常用郵箱：

省份：

詳細地址：

補充說明：

驗證碼：